GSK Rejects £50bn Bid For Consumer Healthcare From Unilever
Executive Summary
GSK says London-based Unilever's £50bn bid for Consumer Healthcare fundamentally undervalues a business which generated sales close to £10bn last year and is expected to grow 4-6% over the medium term. The rejection has not dissuaded Unilever, however, with the company intent on stepping up its presence in the health, beauty and hygiene categories.
You may also be interested in...
Unilever Vows No GSK-Sized Ventures For Foreseeable Future, Commits To Existing Brands In 2022
Opening the company’s fiscal 2021 full-year earnings call, Unilever leadership assured investors it will not make any GSK-sized offers in the foreseeable future as it commits to organic growth and reshaping its portfolio more surgically through bolt-on deals and selective disposals.
Unilever’s Sale Of Thailand Direct Selling Business Doesn’t Quiet Investors Calling For Change
Response to sale of Unilever’s direct selling business in Thailand, Unilever Life, like its recent failed bid for GSK consumer and its elimination of 1,500 management staff, exposes disconnect between its priorities and its shareholders preferences.
Sanofi Not Distracted By M&A Chatter As It Gets Back On Par With Market Growth
Recent market interest shown in other OTC assets will not distract Sanofi from its long-term plan to overhaul its Consumer Healthcare business, says CEO Paul Hudson. And this plan is delivering results, with Sanofi back on par with the consumer health market, posting sales up by 5% in 2021.